

# Checkpoint Inhibitors for Treating Cancer Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

<https://marketpublishers.com/r/C8222CC6129EEN.html>

Date: November 2020

Pages: 90

Price: US\$ 2,800.00 (Single User License)

ID: C8222CC6129EEN

## Abstracts

### SUMMARY

Further key aspects of the report indicate that:

Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology

Chapter 2: Global Industry Summary

Chapter 3: Market Dynamics

Chapter 4: Global Market Segmentation by region, type and End-Use

Chapter 5: North America Market Segmentation by region, type and End-Use

Chapter 6: Europe Market Segmentation by region, type and End-Use

Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use

Chapter 8: South America Market Segmentation by region, type and End-Use

Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.

Chapter 10: Market Competition by Companies

Chapter 11: Market forecast and environment forecast.

Chapter 12: Industry Summary

The global Checkpoint Inhibitors for Treating Cancer market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f.

Factors driving the market for @@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.

Based on the type of product, the global Checkpoint Inhibitors for Treating Cancer market segmented into

Melanoma treatment

PD-L1 inhibitors

CTLA-4 inhibitors

Based on the end-use, the global Checkpoint Inhibitors for Treating Cancer market classified into

Melanoma treatment

Bladder cancer treatment

Others

Based on geography, the global Checkpoint Inhibitors for Treating Cancer market segmented into

North America [U.S., Canada, Mexico]

Europe [Germany, UK, France, Italy, Rest of Europe]

Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]

South America [Brazil, Argentina, Rest of Latin America]

Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]

And the major players included in the report are

Bristol-Myers Squibb(BMS)

Merck

Roche



## Contents

### **1 RESEARCH SCOPE**

- 1.1 Research Product Definition
- 1.2 Research Segmentation
  - 1.2.1 Product Type
  - 1.2.2 Main product Type of Major Players
- 1.3 Demand Overview
- 1.4 Research Methodology

### **2 GLOBAL CHECKPOINT INHIBITORS FOR TREATING CANCER INDUSTRY**

- 2.1 Summary about Checkpoint Inhibitors for Treating Cancer Industry
- 2.2 Checkpoint Inhibitors for Treating Cancer Market Trends
  - 2.2.1 Checkpoint Inhibitors for Treating Cancer Production & Consumption Trends
  - 2.2.2 Checkpoint Inhibitors for Treating Cancer Demand Structure Trends
- 2.3 Checkpoint Inhibitors for Treating Cancer Cost & Price

### **3 MARKET DYNAMICS**

- 3.1 Manufacturing & Purchasing Behavior in 2020
- 3.2 Market Development under the Impact of COVID-19
  - 3.2.1 Drivers
  - 3.2.2 Restraints
  - 3.2.3 Opportunity
  - 3.2.4 Risk

### **4 GLOBAL MARKET SEGMENTATION**

- 4.1 Region Segmentation (2017 to 2021f)
  - 4.1.1 North America (U.S., Canada and Mexico)
  - 4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
  - 4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
  - 4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
  - 4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
- 4.2 Product Type Segmentation (2017 to 2021f)

- 4.2.1 PD-1 inhibitors
- 4.2.2 PD-L1 inhibitors
- 4.2.3 CTLA-4 inhibitors
- 4.3 Consumption Segmentation (2017 to 2021f)
  - 4.3.1 Melanoma treatment
  - 4.3.2 Bladder cancer treatment
  - 4.3.3 Others

## **5 NORTH AMERICA MARKET SEGMENT**

- 5.1 Region Segmentation (2017 to 2021f)
  - 5.1.1 U.S.
  - 5.1.2 Canada
  - 5.1.3 Mexico
- 5.2 Product Type Segmentation (2017 to 2021f)
  - 5.2.1 PD-1 inhibitors
  - 5.2.2 PD-L1 inhibitors
  - 5.2.3 CTLA-4 inhibitors
- 5.3 Consumption Segmentation (2017 to 2021f)
  - 5.3.1 Melanoma treatment
  - 5.3.2 Bladder cancer treatment
  - 5.3.3 Others
- 5.4 Impact of COVID-19 in North America

## **6 EUROPE MARKET SEGMENTATION**

- 6.1 Region Segmentation (2017 to 2021f)
  - 6.1.1 Germany
  - 6.1.2 UK
  - 6.1.3 France
  - 6.1.4 Italy
  - 6.1.5 Rest of Europe
- 6.2 Product Type Segmentation (2017 to 2021f)
  - 6.2.1 PD-1 inhibitors
  - 6.2.2 PD-L1 inhibitors
  - 6.2.3 CTLA-4 inhibitors
- 6.3 Consumption Segmentation (2017 to 2021f)
  - 6.3.1 Melanoma treatment
  - 6.3.2 Bladder cancer treatment

6.3.3 Others

6.4 Impact of COVID-19 in Europe

## **7 ASIA-PACIFIC MARKET SEGMENTATION**

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 PD-1 inhibitors

7.2.2 PD-L1 inhibitors

7.2.3 CTLA-4 inhibitors

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 Melanoma treatment

7.3.2 Bladder cancer treatment

7.3.3 Others

7.4 Impact of COVID-19 in Europe

## **8 SOUTH AMERICA MARKET SEGMENTATION**

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 PD-1 inhibitors

8.2.2 PD-L1 inhibitors

8.2.3 CTLA-4 inhibitors

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 Melanoma treatment

8.3.2 Bladder cancer treatment

8.3.3 Others

8.4 Impact of COVID-19 in Europe

## **9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION**

- 9.1 Region Segmentation (2017 to 2021f)
  - 9.1.1 GCC
  - 9.1.2 North Africa
  - 9.1.3 South Africa
  - 9.1.4 Rest of Middle East and Africa
- 9.2 Product Type Segmentation (2017 to 2021f)
  - 9.2.1 PD-1 inhibitors
  - 9.2.2 PD-L1 inhibitors
  - 9.2.3 CTLA-4 inhibitors
- 9.3 Consumption Segmentation (2017 to 2021f)
  - 9.3.1 Melanoma treatment
  - 9.3.2 Bladder cancer treatment
  - 9.3.3 Others
- 9.4 Impact of COVID-19 in Europe

## **10 COMPETITION OF MAJOR PLAYERS**

- 10.1 Brief Introduction of Major Players
  - 10.1.1 Bristol-Myers Squibb(BMS)
  - 10.1.2 Merck
  - 10.1.3 Roche
- 10.2 Checkpoint Inhibitors for Treating Cancer Sales Date of Major Players (2017-2020e)
  - 10.2.1 Bristol-Myers Squibb(BMS)
  - 10.2.2 Merck
  - 10.2.3 Roche
- 10.3 Market Distribution of Major Players
- 10.4 Global Competition Segmentation

## **11 MARKET FORECAST**

- 11.1 Forecast by Region
- 11.2 Forecast by Demand
- 11.3 Environment Forecast
  - 11.3.1 Impact of COVID-19
  - 11.3.2 Geopolitics Overview
  - 11.3.3 Economic Overview of Major Countries

## 12 REPORT SUMMARY STATEMENT



## List Of Tables

### LIST OF TABLES

1. Table Checkpoint Inhibitors for Treating Cancer Product Type Overview
2. Table Checkpoint Inhibitors for Treating Cancer Product Type Market Share List
3. Table Checkpoint Inhibitors for Treating Cancer Product Type of Major Players
4. Table Brief Introduction of Bristol-Myers Squibb(BMS)
5. Table Brief Introduction of Merck
6. Table Brief Introduction of Roche
7. Table Products & Services of Bristol-Myers Squibb(BMS)
8. Table Products & Services of Merck
9. Table Products & Services of Roche
10. Table Market Distribution of Major Players
11. Table Global Major Players Sales Revenue (Million USD) 2017-2020e
12. Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
13. Table Global Checkpoint Inhibitors for Treating Cancer Market Forecast (Million USD) by Region 2021f-2026f
14. Table Global Checkpoint Inhibitors for Treating Cancer Market Forecast (Million USD) Share by Region 2021f-2026f
15. Table Global Checkpoint Inhibitors for Treating Cancer Market Forecast (Million USD) by Demand 2021f-2026f
16. Table Global Checkpoint Inhibitors for Treating Cancer Market Forecast (Million USD) Share by Demand 2021f-2026f

## List Of Figures

### LIST OF FIGURES

1. Figure Global Checkpoint Inhibitors for Treating Cancer Market Size under the Impact of COVID-19, 2017-2021f (USD Million)
2. Figure Global Checkpoint Inhibitors for Treating Cancer Market by Region under the Impact of COVID-19, 2017-2021f (USD Million)
3. Figure Global Checkpoint Inhibitors for Treating Cancer Market by Product Type under the Impact of COVID-19, 2017-2021f (USD Million)
4. Figure Global Checkpoint Inhibitors for Treating Cancer Market by Demand under the Impact of COVID-19, 2017-2021f (USD Million)
5. Figure Global Checkpoint Inhibitors for Treating Cancer Production by Region under the Impact of COVID-19, 2021-2026 (USD Million)
6. Figure Global Checkpoint Inhibitors for Treating Cancer Consumption by Region under the Impact of COVID-19, 2021-2026 (USD Million)
7. Figure Global Checkpoint Inhibitors for Treating Cancer Consumption by Type under the Impact of COVID-19, 2021-2026 (USD Million)
8. Figure North America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
9. Figure Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
10. Figure Asia-Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
11. Figure South America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
12. Figure Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
13. Figure PD-1 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
14. Figure PD-L1 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
15. Figure CTLA-4 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
16. Figure Melanoma treatment Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
17. Figure Bladder cancer treatment Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
18. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

19. Figure U.S. Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
20. Figure Canada Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
21. Figure Mexico Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
22. Figure PD-1 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
23. Figure PD-L1 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
24. Figure CTLA-4 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
25. Figure Melanoma treatment Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
26. Figure Bladder cancer treatment Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
27. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
28. Figure Germany Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
29. Figure UK Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
30. Figure France Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
31. Figure Italy Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
32. Figure Rest of Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
33. Figure PD-1 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
34. Figure PD-L1 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
35. Figure CTLA-4 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
36. Figure Melanoma treatment Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
37. Figure Bladder cancer treatment Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
38. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-

year (YOY) Growth (%) 2018-2021f

39. Figure China Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

40. Figure India Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

41. Figure Japan Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

42. Figure South Korea Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

43. Figure Southeast Asia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

44. Figure Australia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

45. Figure Rest of Asia Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

46. Figure PD-1 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

47. Figure PD-L1 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

48. Figure CTLA-4 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

49. Figure Melanoma treatment Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

50. Figure Bladder cancer treatment Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

51. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

52. Figure Brazil Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

53. Figure Argentina Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

54. Figure Rest of Latin America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

55. Figure PD-1 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

56. Figure PD-L1 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

57. Figure CTLA-4 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

58. Figure Melanoma treatment Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
59. Figure Bladder cancer treatment Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
60. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
61. Figure GCC Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
62. Figure North Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
63. Figure South Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
64. Figure Rest of Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
65. Figure PD-1 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
66. Figure PD-L1 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
67. Figure CTLA-4 inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
68. Figure Melanoma treatment Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
69. Figure Bladder cancer treatment Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
70. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
71. Figure Checkpoint Inhibitors for Treating Cancer Sales Revenue (Million USD) of Bristol-Myers Squibb (BMS) 2017-2020e
72. Figure Checkpoint Inhibitors for Treating Cancer Sales Revenue (Million USD) of

## I would like to order

Product name: Checkpoint Inhibitors for Treating Cancer Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Product link: <https://marketpublishers.com/r/C8222CC6129EEN.html>

Price: US\$ 2,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C8222CC6129EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

